Editor in Chief Dr KK Aggarwal, Padma Shri Awardee                                                                               Dated:26 July,2020

Health dept to conduct Covid-19 testing at 28 centres

Agra: Following orders of the state government to increase Covid-19 testing, the Agra district health department has established rapid antigen testing facility at 28 centres in the district. Around 10 testing facilities will operate at 10 different primary health centres (PHC) in the city areas and 18 community health centres (CHC) in rural areas. Tests will be conducted after screening of the symptomatic patient.
According to the health department officials, result of the antigen test will come in around 20 minutes. It is a test on nasal swab samples that detects antigens (foreign substances that induce an immune response in the body) that are found on or within the novel coronavirus. It is a point-of-care test, performed outside the conventional laboratory setting, and is used to quickly obtain a diagnostic result....read more


Convalescent Plasma Therapy in COVID-19

Join us today at 7:00 pm as we discuss the management of COVID-19 patients with "convalescent plasma therapy ” in Medtalks with Dr KK Aggarwal COVID edition
Just click on www.facebook.com/drkkaggarwal or https://perfecthealthmela.com/vevent/general-webinar.php


CMAAO Coronavirus Facts and Myth Buster: COVID Drugs Update

With inputs from Dr Monica Vasudev
1007: Redefine cardiac injury marker cut-offs to predict 28 days mortality in COVID-19 inpatients
The abnormal cardiac biomarker pattern that is observed in patients with COVID-19 has a significant association with an increased risk of death. The cut-offs of these markers for effective prognosis of 28-day mortality of COVID-19 seems to be much lower than that for regular heart disease, at 49% of currently recommended thresholds, suggests a study published in Hypertension. ,The biomarkers include high-sensitivity cardiac troponin I (hs-cTnI), creatine kinase-MB (CK-MB), NT-proB-type natriuretic peptide (NT-proBNP), creatine phosphokinase (CK) and myoglobin (MYO). ....read more


World COVID Meter 25th July: India Number 3, 213 Countries Affected

Cases: 1M April 2, 2M April 15, 3M April 27, 4M May 8, 5M May 20, 6M May 30, 7M June 7, 8M June 15, 9M June 22, 10M June 29th, 11M July 4, 12M July 8, 13M July 13, 14M July 17, 15M July 23
Ground Zero: Wuhan - in live animal market or cafeteria for animal pathogens: 10th January; Total cases are based on RT PCR, 67% sensitivity ,Coronavirus Cases: 15,939,175,Deaths: 642,622,Recovered: 9,723,365,ACTIVE CASES: 5,573,188 Currently Infected Patients....read more


You look at people the same way as you are

Honest people regard everybody as honest and dishonest people regard everybody as dishonest. It all depends on the type of people you interact with. If you do not take bribe, nobody will come and offer bribe to you and you will feel everybody is honest. If you take bribe then everybody will come to you to offer bribe and you will feel that everybody in the society is dishonest.
Never judge people with your personal experience. I recall a doctor saying that every doctor takes and gives bribe because he was running an imaging center and every doctor who approached him asked for a bribe. But he did not take into consideration the doctors who did not approach him. ....read more


Video of The day

COVID 19 Diagnosis made easy


Medbytes

       


Healthcare News Monitor
CVD drugs, prescription records high; cough and cold dips in June second half: Wisdom Insight
Express Pharma

Immunity booster and vitamin continue to be in purchase preference
The second half of June month witnessed growth momentum in the pharmaceutical products purchase, especially in the cardiovascular (CVD) therapeutic areas. According to a research report of Wisdom Insight, during second half of June 2020, the medical prescription of CVD drugs recorded a clear uptrend in pharma purchase. Although, the immunity-linked products continued to have a strong purchase preference in the similar period.

Cipla gets DCGI approval to sell Covid-19 drug favipiravir in India
Business Standard

Cipla Ltd has received Indian regulatory approval to sell anti-viral drug favipiravir to treat Covid-19, the drugmaker said on Friday, as coronavirus infections in the world's third worst-hit nation show no sign of abating. ,The Drug Controller General of India granted Cipla accelerated approval to make and sell favipiravir in an effort to meet the "urgent and unmet" need for Covid-19 treatment options in the country, the company said. ,Indian drugmakers including Glenmark Pharmaceuticals Ltd are racing to supply generic versions of favipiravir, originally developed by Japan's Fujifilm Holdings Corp as Avigan for treating influenza.

How a team of doctors in Kochi saved a 5-year-old with rare ‘P null’ blood group
TheNewsMinute

At the end of April this year, Dr Veena Shenoy and her team at the Department of Transfusion Medicine at the Amrita Institute of Medical Sciences (AIMS), Kochi, handled the case of a five-year-old patient from Gujarat who had suffered a serious fall and was in need of surgery. Dr Veena looked at the child’s reports and saw something which she had until then only seen in medical textbooks and journals: P null phenotype. ,“The hospital in Surat got the child’s sample tested from the New York Blood Centre and she was then brought to Kerala for further treatment,” Dr Veena tells TNM.